Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Add filters

Year range
Preprint in English | MEDLINE | ID: ppcovidwho-290700


The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can result in a hyperinflammatory state, leading to acute respiratory distress syndrome (ARDS), myocardial injury, and thrombotic complications, among other sequelae. Statins, which are known to have anti-inflammatory and antithrombotic properties, have been studied in the setting of other viral infections and ARDS, but their benefit has not been assessed in COVID-19. Thus, we sought to determine whether antecedent statin use is associated with lower in-hospital mortality in patients hospitalized for COVID-19. This is a retrospective analysis of patients admitted with COVID-19 from February 1 st through May 12 th , 2020 with study period ending on June 11 th , 2020. Antecedent statin use was assessed using medication information available in the electronic medical record. We constructed a multivariable logistic regression model to predict the propensity of receiving statins, adjusting for baseline socio-demographic and clinical characteristics, and outpatient medications. The primary endpoint included in-hospital mortality within 30 days. A total of 2626 patients were admitted during the study period, of whom 951 (36.2%) were antecedent statin users. Among 1296 patients (648 statin users, 648 non-statin users) identified with 1:1 propensity-score matching, demographic, baseline, and outpatient medication information were well balanced. Statin use was significantly associated with lower odds of the primary endpoint in the propensity-matched cohort (OR 0.48, 95% CI 0.36 a" 0.64, p<0.001). We conclude that antecedent statin use in patients hospitalized with COVID-19 was associated with lower inpatient mortality. Randomized clinical trials evaluating the utility of statin therapy in patients with COVID-19 are needed.

American Journal of Respiratory and Critical Care Medicine ; 203(9):2, 2021.
Article in English | Web of Science | ID: covidwho-1407143
American Journal of Respiratory and Critical Care Medicine ; 203(9), 2021.
Article in English | EMBASE | ID: covidwho-1277343


Rationale: Higher levels of circulating interleukin-6 (IL-6) and lower respiratory system compliance have each been associated with increased mortality in severe coronavirus 2019 (COVID-19). IL-6 levels are associated with disease severity and mortality in non-COVID-19-related acute respiratory distress syndrome (ARDS). The purpose of this study was to examine the relationship between IL-6 and respiratory mechanics in COVID-19-related ARDS. Methods: This retrospective cohort study took place at two Columbia University Irving Medical Center hospitals. We identified patients age >18 years with laboratory confirmed COVID-19, who were intubated from March 1st through April 30th, 2020, and met the Berlin definition of ARDS. Electronic medical records were reviewed for clinical data. Outcomes were censored at 90 days after intubation. For patients without IL-6 levels recorded on the initial day of intubation, serum samples were obtained from the Columbia University Biobank and tested using the Quantikine Human IL-6 Immunoassay. IL-6 values were log-transformed. The primary outcome was respiratory system compliance. Secondary outcomes were calculated ventilatory ratio, PaO2:FiO2 ratio, and mortality. Linear regression and logistic regression were used for statistical analyses. Results: During the study period, 483 patients had COVID-19-associated ARDS. Median time of follow up was 37 days (IQR 11-90). At 90 days, 260 (53.8%) patients were deceased, 206 (42.7%) had been discharged, and 17 (3.5%) were still admitted. Two hundred sixteen (44.7%) patients had available data on respiratory system compliance and serum IL-6 levels from the initial day of mechanical ventilation. The median IL-6 value was 204.1 pg/ml (IQR 110-469.7). Median compliance was 25.5 ml/cmH2O (IQR 21.4-33.3), median ventilatory ratio was 1.96 (IQR 1.51-2.57), and median PaO2:FiO2 ratio was 134 (IQR 87-196). In unadjusted linear regression, higher IL-6 was associated with lower respiratory system compliance (log [IL-6] coefficient-1.80, p = 0.001) (Figure 1). This relationship remained significant when adjusting for age, sex, body mass index, race, ethnicity, and Sequential Organ Failure Assessment (SOFA) score (coefficient-2.43, p<0.001). There was no significant association between IL-6 and ventilatory ratio (0.76 p=0.08) or PaO2:FiO2 ratio (-6.15 p=0.06). Higher IL-6 was associated with higher odds of death at 90 days (OR 1.35 per unit increase in log [IL-6], p-value 0.022) when adjusting for age, sex, body mass index, race, ethnicity, and SOFA score. Conclusion: In COVID-19-associated ARDS, higher levels of IL-6 were associated with lower respiratory system compliance even adjusting for measured confounders. Higher IL-6 was also associated with higher mortality.